Syntec Brasil

What Syntec Brasil does

Syntec Brasil is a privately held Brazilian veterinary pharmaceutical manufacturer founded in 2004 and headquartered in Barueri (Tamboré), São Paulo. The company develops, manufactures, and commercializes a broad portfolio of animal health products — including anesthetics, anti-inflammatories, antibiotics, dermatologicals, ophthalmologicals, nutritional supplements, and vaccines — across six species categories: dogs, cats, equines, poultry, swine, and production animals (bovine). Its primary technical differentiator is a proprietary SR-MCT thixotropic formulation technology used in the T@urus SR antiparasitic, which enables slow and prolonged active release with greater fluidity. The portfolio was extended in 2024 with two launches: Trilostec, a trilostane-based treatment for canine Cushing's syndrome, and Leptotec 8, a bovine leptospirosis vaccine positioned as the only Brazilian product with three Hardjo serovars and a CFM adjuvant.

The company's go-to-market relies on third-party distribution through veterinary clinics, pet stores, livestock producers, and dedicated distributors, with a Brazilian-only geographic footprint. Commercial operations are organized along species lines, evidenced by a National Sales Manager for Large Animals and a separate Pet Line Product Coordinator. Marketing is executed through an owned blog and segmented Instagram channels (syntecpets, syntecgrandesanimais) targeting veterinarians, breeders, retailers, distributors, and pet owners. The company is privately owned, 100% domestically held, and discloses no institutional investors, funding rounds, or revenue figures. Pricing is not publicly available; customers must contact the company directly for quotes via phone or email.

The business model is a traditional B2B/B2B2C veterinary pharma manufacturer model: production and sale of regulated medications and supplements, monetized through distributor and reseller margins rather than direct-to-consumer pricing. Customer segments are diversified across companion animals, equines, and livestock, which provides some buffer against single-species demand cycles but ties revenue closely to Brazilian agricultural and pet-care market dynamics. No AI, software, or digital platform component is part of the disclosed offering.

Name

Syntec Brasil

Legal name

Syntec Brasil

Website

https://syntec.com.br

Company type

Private

Founded year

2004

Operating status

Operating

Short description

Syntec Brasil is a privately held Brazilian veterinary pharmaceutical manufacturer that develops, produces, and sells medications, supplements, and vaccines for dogs, cats, equines, poultry, swine, and production animals, distributed through veterinary clinics, pet stores, and livestock channels within Brazil.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Immune Support Supplements (HLAMALAE)

Keywords

• Veterinary pharmaceuticals
• Animal health products
• Veterinary vaccines
• Livestock medications
• Pet supplements

Headquarters

HQ city

Santana De Parnaíba

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

Syntec Brasil is a Brazilian veterinary pharmaceutical manufacturer that produces and commercializes a broad portfolio of medications, supplements, and vaccines for pets (dogs and cats), equines, and production animals (bovine, swine, poultry). The portfolio spans anesthetics, anti-inflammatories, antibiotics, dermatologicals, ophthalmologicals, supplements, and vaccines, with proprietary formulations such as SR-MCT tixotropic technology in antiparasitic products and the CFM adjuvant in bovine vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• Trilostec Veterinary pharmaceutical for the treatment of hyperadrenocorticism (Cushing's syndrome) in dogs, containing trilostane as the active ingredient in palatable tablet form. Marketed to veterinarians and pet owners managing endocrine disorders in dogs.
• Leptotec 8 Bovine vaccine for prevention of leptospirosis in cattle, containing sorovar Hardjo and other serovars with the CFM adjuvant to reduce vaccine reactions. Marketed to livestock producers and veterinarians for herd health management in tropical and subtropical climates.
• T@urus SR antiparasitic Antiparasitic veterinary product utilizing proprietary SR-MCT tixotropic technology for slow and prolonged release of active ingredients with improved fluidity. Marketed for parasite control in cattle and other animals.

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• MSD Animal Health: Animal health division of Merck offering a full range of pharmaceuticals, vaccines, and parasiticides. Direct overlap with Syntec's portfolio across companion and production animal segments in Brazil.
• Boehringer Ingelheim Animal Health: Top-three global animal health player offering vaccines, parasiticides, and pharmaceuticals for production animals and pets. Major competitor to Syntec in the Brazilian livestock vaccine and therapeutic markets.
• Elanco Animal Health: Global animal health company with leading positions in parasiticides, vaccines, and therapeutics for both pets and livestock. Competes with Syntec across all major product categories globally and in Brazil.
• Ceva Santé Animale: Global animal health company with strong presence in Brazil and Latin America, offering vaccines, pharmaceuticals, and reproductive technologies for production animals and pets. Overlaps Syntec's therapeutic and vaccine categories but operates at materially larger scale.
• Zoetis: World's largest animal health company with a comprehensive portfolio of pharmaceuticals, vaccines, diagnostics, and parasiticides across all major species. Competes directly with Syntec across every product category but at significantly larger scale and global reach.

Direct peers

• Hipra: Spanish veterinary biologics and pharmaceutical company specializing in vaccines and specialty therapeutics for livestock and companion animals. Comparable portfolio composition, with similar emphasis on vaccine technology platforms.
• Ourofino Saúde Animal: Brazilian veterinary pharmaceutical manufacturer producing pharmaceuticals, vaccines, and specialty products for livestock and companion animals. Most direct comparable given shared geography, multi-species portfolio, and Brazilian manufacturing base.
• Virbac: France-based veterinary pharmaceutical company focused exclusively on animal health with a portfolio spanning vaccines, parasiticides, antibiotics, and specialty therapeutics across companion and production animals, directly comparable to Syntec's product mix.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceutical company focused on therapeutics for companion animals, particularly endocrinology, dermatology, and ophthalmology — categories Syntec explicitly addresses with Trilostec and its dermatological/ophthalmological lines.
• Vetoquinol: Independent French veterinary pharmaceutical group producing therapeutics and supplements for companion animals and livestock. Comparable mid-tier scale and portfolio breadth to Syntec.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/syntecpets
• LinkedInlinkedin.com/company/syntec-do-brasil

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syntec Brasil